Zenas Biopharma宣布Obexelimab三期INDIGO试验达成主要及所有关键次要终点

投资观察
Jun 03

Zenas Biopharma Inc. 公布,其候选药物Obexelimab在针对免疫球蛋白G4相关疾病(IgG4-RD)的关键注册性三期INDIGO试验中,成功达成了主要终点以及所有关键的次要终点。

相关数据已在2026年欧洲抗风湿病联盟(EULAR)大会上同步发布,并同期发表于《新英格兰医学杂志》。试验结果显示,Obexelimab治疗显著降低了糖皮质激素的使用剂量及其相关毒性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10